Loading…
Reported covered position: SA to Sen Lugar, 06-07
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Intelligence Authorization Act for Fiscal Year 2024
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 3932/S. 2076 - PASTEUR Act; PAHPA reauthorization; issues related to drug pricing policy.
SERVE Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 3932/S. 2076 - PASTEUR Act; PAHPA reauthorization; issues related to drug pricing policy.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2023 · second_quarter · Q2
Fiscal Year 2024 appropriations for dangers of fentanyl awareness campaign and Customs and Border Protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Source: Senate LDA
| AKEBIA THERAPEUTICS, INC. |
| 9 |
| 2019–2021 |
| INARI MEDICAL | 8 | 2021–2023 |
| CHRISTUS HEALTH SYSTEM | 7 | 2014–2015 |
| XENEX DISINFECTION SERVICES LLC | 7 | 2014–2020 |
| PARTNERSHIP FOR MEDICAID HOME-BASED CARE | 6 | 2022–2023 |
| SENSEONICS INCORPORATED | 6 | 2019–2021 |
| EMPRESAS FONALLEDAS, INC. | 5 | 2019–2020 |
| NETWORK FOR REGIONAL HEALTHCARE IMPROVEMENT | 5 | 2015–2016 |
| SYRACUSE UNIVERSITY | 5 | 2019 |
| TEXAS ASSOCIATION FOR HOME CARE & HOSPICE | 5 | 2015–2021 |
| TRANSUNION | 5 | 2021–2022 |
| APPRISS, INC. | 4 | 2020–2021 |
| KIDNEY CARE PARTNERS | 4 | 2014 |
| SURGERY PARTNERS | 4 | 2020 |
| AHS MANAGEMENT COMPANY, INC | 3 | 2022–2023 |
| FINTHRIVE, INC. | 3 | 2022 |
| FMR LLC | 3 | 2020 |
| Sight Sciences, Inc. | 3 | 2020–2021 |
| ZELIS HEALTHCARE CORPORATION | 3 | 2019–2020 |
| ZP BETTER TOGETHER, LLC | 3 | 2020 |
| CORECIVIC, INC. | 2 | 2022 |
| AMERICAN COUNCIL OF LIFE INSURERS | 1 | 2019 |
| Global Healthcare Exchange, LLC | 1 | 2020 |
| LORETTO MANAGEMENT CORP | 1 | 2014 |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | 1 | 2020 |
| MINOR LEAGUE BASEBALL RELIEF, INC | 1 | 2021 |
| ZERO TECHNOLOGIES LLC D/B/A ZEROWATER | 1 | 2023 |
Cures 2.0 Act
Client: PARTNERSHIP FOR MEDICAID HOME-BASED CARE · Firm: AKIN GUMP STRAUSS HAUER & FELD
Medicaid home- and community-based services funding; H.R. 6000, Cures 2.0 Act (Section 409) - 117th Congress; alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing; workforce issues.
Issues related to fentanyl: Bruce's Law (H.R. 9221 / S. 4358, 117th Congress); and incentives for state participation in existing national data reporting tools to inform overdose prevention efforts and target naloxone distribution.
Issues related to fentanyl: Bruce's Law (H.R. 9221 / S. 4358, 117th Congress); and incentives for state participation in existing national data reporting tools to inform overdose prevention efforts and target naloxone distribution.
Alternative Data for Additional Credit FHA Pilot Program Reauthorization Act
Client: TRANSUNION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to credit reporting -- National Credit Reporting Agency Act, Protecting Your Credit Score Act, Comprehensive Consumer Credit Reporting Reform Act (H.R. 4120), Credit Access and Inclusion Act (S. 2417), Alternative Data for Additional Credit FHA Pilot Program Reauthorization Act (H.R. 123), Building Credit Access for Veterans Act (S. 1838).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Synthetic Opioid Danger Awareness Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Synthetic Opioid Danger Awareness Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Synthetic Opioid Danger Awareness Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Synthetic Opioid Danger Awareness Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Social Determinants Accelerator Act of 2021
Client: FINTHRIVE, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Social Determinants Accelerator Act of 2021 (S. 3039 / H.R. 2503).
Social Determinants Accelerator Act of 2021
Client: FINTHRIVE, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Social Determinants Accelerator Act (H.R. 2503/S. 3039).
Social Determinants Accelerator Act of 2021
Client: FINTHRIVE, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Social Determinants Accelerator Act of 2021 (S. 3039 / H.R. 2503).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Issues related to credit reporting -- National Credit Reporting Agency Act, Protecting Your Credit Score Act, Comprehensive Consumer Credit Reporting Reform Act (H.R. 4120), Credit Access and Inclusion Act (S. 2417), Alternative Data for Additional Credit FHA Pilot Program Reauthorization Act (H.R. 123), Building Credit Access for Veterans Act (S. 1838).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 4479, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021; issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth; issues related to COVID-19 testing; H.R. 4479/S. 2609 - the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021.
Collaborate in an Orderly and Cohesive Manner Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Collaborate in an Orderly and Cohesive Manner Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Collaborate in an Orderly and Cohesive Manner Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Collaborate in an Orderly and Cohesive Manner Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Inflation Reduction Act of 2022
Client: PARTNERSHIP FOR MEDICAID HOME-BASED CARE · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 5376 (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing.
Inflation Reduction Act of 2022
Client: PARTNERSHIP FOR MEDICAID HOME-BASED CARE · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 5376, Build Back Better Act (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); Fiscal Year 2022 appropriations for the Provider Relief Fund.
Inflation Reduction Act of 2022
Client: PARTNERSHIP FOR MEDICAID HOME-BASED CARE · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 5376 (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing.
Inflation Reduction Act of 2022
Client: PARTNERSHIP FOR MEDICAID HOME-BASED CARE · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 5376, Build Back Better Act (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing.
Cures 2.0 Act
Client: PARTNERSHIP FOR MEDICAID HOME-BASED CARE · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 5376 (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing.
Cures 2.0 Act
Client: PARTNERSHIP FOR MEDICAID HOME-BASED CARE · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 5376, Build Back Better Act (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); Fiscal Year 2022 appropriations for the Provider Relief Fund.
Cures 2.0 Act
Client: PARTNERSHIP FOR MEDICAID HOME-BASED CARE · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 5376, Build Back Better Act (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing.
Cures 2.0 Act
Client: PARTNERSHIP FOR MEDICAID HOME-BASED CARE · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 5376 (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing.
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Building Credit Access for Veterans Act of 2021
Client: TRANSUNION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to credit reporting -- National Credit Reporting Agency Act, Protecting Your Credit Score Act, Comprehensive Consumer Credit Reporting Reform Act (H.R. 4120), Credit Access and Inclusion Act (S. 2417), Alternative Data for Additional Credit FHA Pilot Program Reauthorization Act (H.R. 123), Building Credit Access for Veterans Act (S. 1838).
PASTEUR Act of 2021
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
National Vaccine Injury Compensation Program issues; Consolidated Appropriations Act, 2023 (P.L. 117-328); PAHPA reauthorization; policy riders related to reauthorization of the FDA user fee agreements, PASTEUR Act of 2021 (S. 2076).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Credit Access and Inclusion Act of 2021
Client: TRANSUNION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to credit reporting -- National Credit Reporting Agency Act, Protecting Your Credit Score Act, Comprehensive Consumer Credit Reporting Reform Act (H.R. 4120), Credit Access and Inclusion Act (S. 2417), Alternative Data for Additional Credit FHA Pilot Program Reauthorization Act (H.R. 123), Building Credit Access for Veterans Act (S. 1838).
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 4479, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021; issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth; issues related to COVID-19 testing; H.R. 4479/S. 2609 - the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Social Determinants Accelerator Act of 2021
Client: FINTHRIVE, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Social Determinants Accelerator Act of 2021 (S. 3039 / H.R. 2503).
Social Determinants Accelerator Act of 2021
Client: FINTHRIVE, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Social Determinants Accelerator Act of 2021 (S. 3039 / H.R. 2503).
Social Determinants Accelerator Act of 2021
Client: FINTHRIVE, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Social Determinants Accelerator Act (H.R. 2503/S. 3039).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Eliminating the Provider Relief Fund Tax Penalties Act of 2021
Client: AIR EVAC LIFETEAM · Firm: AKIN GUMP STRAUSS HAUER & FELD
Air Ambulance and Patient Billing Advisory Committee, and implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); eliminating the Provider Relief Fund Tax Penalties Act of 2021 (H.R. 2079)
Eliminating the Provider Relief Fund Tax Penalties Act of 2021
Client: AIR EVAC LIFETEAM · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); eliminating the Provider Relief Fund Tax Penalties Act of 2021 (H.R. 2079).
Social Determinants Accelerator Act of 2021
Client: TRANSUNION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the Health IT Advisory Committee; H.R. 2503, Social Determinants Accelerator Act of 2021.
Social Determinants Accelerator Act of 2021
Client: TRANSUNION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Social Determinants Accelerator Act of 2021 (H.R. 2503)
Home Health Emergency Access to Telehealth Act
Client: TEXAS ASSOCIATION FOR HOME CARE & HOSPICE · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to home care and hospice, telehealth, Medicare reimbursement and state's health insurance program legislation.; Legislative and regulatory proposals affecting home care and hospice.; Home health rural add on payment adjustment.; Value based purchasing and bundling.; Hospice payment policy.; Home health non-physician certification authority.; Chronic care management proposals.; Medicare Advantage hospice proposals.; CMS Home Health Conditions of Participation.; Home Health Pre-Claim Review Demonstration program.; Disposal of controlled substances.; Review Choice Demonstration; Impact of COVID-19, including telehealth.; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response; Issues related to home care and hospice, telehealth, Medicare reimbursement.; Impact of COVID-19, including telehealth and the Provider Relief Fund.; COVID-19 relief funding within the American Rescue Plan Act (P.L. 117-2), HEAT Act (S. 4854/H.R.3371),; FY 2022 Appropriations, 1115 Waiver, and FMAP increase/HCBS.; HEAT Act (H.R. 3371).
Home Health Emergency Access to Telehealth Act
Client: TEXAS ASSOCIATION FOR HOME CARE & HOSPICE · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to home care and hospice, telehealth, Medicare reimbursement and state's health insurance program legislation.; Legislative and regulatory proposals affecting home care and hospice.; Home health rural add on payment adjustment.; Value based purchasing and bundling.; Hospice payment policy.; Home health non-physician certification authority.; Chronic care management proposals.; Medicare Advantage hospice proposals.; CMS Home Health Conditions of Participation.; Home Health Pre-Claim Review Demonstration program.; Disposal of controlled substances.; Review Choice Demonstration; Impact of COVID-19, including telehealth.; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response; Issues related to home care and hospice, telehealth, Medicare reimbursement.; Impact of COVID-19, including telehealth and the Provider Relief Fund.; COVID-19 relief funding within the American Rescue Plan Act (P.L. 117-2), HEAT Act (S. 4854/H.R.3371),; FY 2022 Appropriations, 1115 Waiver, and FMAP increase/HCBS.; HEAT Act (H.R. 3371).
Minor League Baseball Relief Act
Client: MINOR LEAGUE BASEBALL RELIEF, INC · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the Minor League Baseball COVID Relief Act, H.R. 4150 and S. 2233.
Minor League Baseball Relief Act
Client: MINOR LEAGUE BASEBALL RELIEF, INC · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the Minor League Baseball COVID Relief Act, H.R. 4150 and S. 2233.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Social Determinants Accelerator Act of 2021
Client: TRANSUNION · Firm: AKIN GUMP STRAUSS HAUER & FELD
S. 3039, Social Determinants Accelerator Act of 2021.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Families First Coronavirus Response Act
Client: TEXAS ASSOCIATION FOR HOME CARE & HOSPICE · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to home care and hospice, telehealth, Medicare reimbursement and state's health insurance program legislation.; Legislative and regulatory proposals affecting home care and hospice.; Home health rural add on payment adjustment.; Value based purchasing and bundling.; Hospice payment policy.; Home health non-physician certification authority.; Chronic care management proposals.; Medicare Advantage hospice proposals.; CMS Home Health Conditions of Participation.; Home Health Pre-Claim Review Demonstration program.; Disposal of controlled substances.; Review Choice Demonstration; Impact of COVID-19, including telehealth.; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response; Issues related to home care and hospice, telehealth, Medicare reimbursement.; Impact of COVID-19, including telehealth and the Provider Relief Fund.; COVID-19 relief funding within the American Rescue Plan Act (P.L. 117-2), HEAT Act (S. 4854/H.R.3371),; FY 2022 Appropriations, 1115 Waiver, and FMAP increase/HCBS.; HEAT Act (H.R. 3371).
Families First Coronavirus Response Act
Client: TEXAS ASSOCIATION FOR HOME CARE & HOSPICE · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to home care and hospice, telehealth, Medicare reimbursement and state's health insurance program legislation.; Legislative and regulatory proposals affecting home care and hospice.; Home health rural add on payment adjustment.; Value based purchasing and bundling.; Hospice payment policy.; Home health non-physician certification authority.; Chronic care management proposals.; Medicare Advantage hospice proposals.; CMS Home Health Conditions of Participation.; Home Health Pre-Claim Review Demonstration program.; Disposal of controlled substances.; Review Choice Demonstration; Impact of COVID-19, including telehealth.; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response.
H.R. 3932/S. 2076 - PASTEUR Act; PAHPA reauthorization; issues related to drug pricing policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Issues related to fentanyl: Bruce's Law (H.R. 9221 / S. 4358, 117th Congress); and incentives for state participation in existing national data reporting tools to inform overdose prevention efforts and target naloxone distribution.
Fiscal Year 2024 appropriations for dangers of fentanyl awareness campaign, the Practitioner Education Grant Program, and Customs and Border Protection.
Issues related to fentanyl: conditioning foreign aid; implementation of the Fentanyl Sanctions Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR MEDICAID HOME-BASED CARE via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Medicaid home- and community-based services funding; H.R. 6000, Cures 2.0 Act (Section 409) - 117th Congress; alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing; workforce issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AHS MANAGEMENT COMPANY, INC via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Issues related to American Rescue Plan Act Provider Relief Fund Rural Payment Distribution.
Filing targets: SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Issues related to the health care workforce and remanufacturing; issues related to medical device remanufacturing; issues related to medical device remanufacturing and health care workforce.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZERO TECHNOLOGIES LLC D/B/A ZEROWATER via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Section 337 public interest issues.
Section 337 public interest issues.
Filing targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Issues regarding health data privacy and cybersecurity.
Issues regarding Medicare reimbursement for digital health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INARI MEDICAL via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Education and awareness of medical device treatments for blood clots.
Fiscal Year 2024 Centers for Disease Control and Prevention (CDC) appropriations for Deep Vein Thrombosis (DVT) and Pulmonary Embolisms (PE) education and awareness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PARTNERSHIP FOR MEDICAID HOME-BASED CARE via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
H.R. 5376 (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Digital health regulation and reimbursement; data privacy; respiratory care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Fiscal Year (FY) 2023 appropriations report language request regarding medical device remanufacturing; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
National Vaccine Injury Compensation Program issues; Consolidated Appropriations Act, 2023 (P.L. 117-328); PAHPA reauthorization; policy riders related to reauthorization of the FDA user fee agreements, PASTEUR Act of 2021 (S. 2076).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INARI MEDICAL via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Education and awareness of medical device treatments for blood clots.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORECIVIC INC via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Implementation of SUPPORT Act Section 5032 (P.L. 115-271). Consistent with CoreCivic policy, Akin Gump does not lobby for or against any policies or legislation that would determine the basis for an individual's incarceration or detention.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FINTHRIVE, INC. via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Social Determinants Accelerator Act of 2021 (S. 3039 / H.R. 2503).
Filing targets: SENATE
CORECIVIC INC via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Implementation of SUPPORT Act Section 5032 (P.L. 115-271).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AHS MANAGEMENT COMPANY, INC via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Issues related to American Rescue Plan Act Provider Relief Fund Rural Payment Distribution.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR MEDICAID HOME-BASED CARE via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
H.R. 5376 (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INARI MEDICAL via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Reimbursement issues regarding clot removing medical devices.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FINTHRIVE, INC. via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Social Determinants Accelerator Act of 2021 (S. 3039 / H.R. 2503).
Filing targets: SENATE
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Issues regarding Medicare reimbursement for digital health.
Digital health regulation and reimbursement; data privacy; respiratory care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AHS MANAGEMENT COMPANY, INC via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · RR
Issues related to Provider Relief Fund Rural Payments.
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Issues regarding Medicare reimbursement for DMEPOS and digital health
Filing targets: HOUSE OF REPRESENTATIVES
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
General issues regarding access to cancer care and treatment; issues re: right to repair proposals; issues re: medical device remanufacturing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
INARI MEDICAL via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Reimbursement issues regarding clot removing medical devices.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR MEDICAID HOME-BASED CARE via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
H.R. 5376, Build Back Better Act (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); alignment of Medicaid and Medicare programs for dual eligible populations to improve care; presumptive eligibility for Medicaid HCBS; establishment of a federal definition of private duty nursing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FINTHRIVE, INC. via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · RR
Social Determinants Accelerator Act (H.R. 2503/S. 3039).
TRANSUNION via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Issues related to credit reporting -- National Credit Reporting Agency Act, Protecting Your Credit Score Act, Comprehensive Consumer Credit Reporting Reform Act (H.R. 4120), Credit Access and Inclusion Act (S. 2417), Alternative Data for Additional Credit FHA Pilot Program Reauthorization Act (H.R. 123), Building Credit Access for Veterans Act (S. 1838).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
H.R. 4479, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021; issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth; issues related to COVID-19 testing; H.R. 4479/S. 2609 - the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR MEDICAID HOME-BASED CARE via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
H.R. 5376, Build Back Better Act (Medicaid home- and community-based services funding); H.R. 6000, Cures 2.0 Act (Section 409); Fiscal Year 2022 appropriations for the Provider Relief Fund.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Medicare coverage of Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); Build Back Better Act health care workforce provisions, Pathway to Health Careers and National Health Services Corps.
Support for Medicaid FMAP increase for emergency transportation services.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Digital health regulation and reimbursement.
Issues regarding Medicare reimbursement for DMEPOS and remote therapeutic monitoring services; issues regarding supply chain
PARTNERSHIP FOR MEDICAID HOME-BASED CARE via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · RR
Issues related to the delivery of Medicaid home-based care.
Issues related to the delivery of Medicaid home-based care.
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Issues regarding Medicare reimbursement for DMEPOS and remote therapeutic monitoring services; issues regarding supply chain
Digital health regulation and reimbursement.
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Issues related to Medicare reimbursement for oncology care and alternative payment models; issues related to telehealth; issues related to COVID-19 testing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, U.S. Trade Representative (USTR), White House Office
TRANSUNION via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
S. 3039, Social Determinants Accelerator Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEXAS ASSOCIATION FOR HOME CARE & HOSPICE via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Issues related to home care and hospice, telehealth, Medicare reimbursement and state's health insurance program legislation.; Legislative and regulatory proposals affecting home care and hospice.; Home health rural add on payment adjustment.; Value based purchasing and bundling.; Hospice payment policy.; Home health non-physician certification authority.; Chronic care management proposals.; Medicare Advantage hospice proposals.; CMS Home Health Conditions of Participation.; Home Health Pre-Claim Review Demonstration program.; Disposal of controlled substances.; Review Choice Demonstration; Impact of COVID-19, including telehealth.; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response; Issues related to home care and hospice, telehealth, Medicare reimbursement.; Impact of COVID-19, including telehealth and the Provider Relief Fund.; COVID-19 relief funding within the American Rescue Plan Act (P.L. 117-2), HEAT Act (S. 4854/H.R.3371),; FY 2022 Appropriations, 1115 Waiver, and FMAP increase/HCBS.; HEAT Act (H.R. 3371).
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INARI MEDICAL via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Education and awareness of medical device treatments for blood clots.
Medicare coverage of transvenous (catheter) pulmonary embolectomy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); Build Back Better Act health care workforce provisions, Pathway to Health Careers and National Health Services Corps.
Implementation of the No Surprises Act as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); issues related to Medicare reimbursement for emergency air ambulance services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); eliminating the Provider Relief Fund Tax Penalties Act of 2021 (H.R. 2079).
Implementation of the No Surprises Act as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); issues related to Medicare reimbursement for emergency air ambulance services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
MINOR LEAGUE BASEBALL RELIEF, INC via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Issues related to the Minor League Baseball COVID Relief Act, H.R. 4150 and S. 2233.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Issues regarding Medicare reimbursement for DMEPOS and remote therapeutic monitoring services; issues regarding supply chain.
Filing targets: HOUSE OF REPRESENTATIVES
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
SIGHT SCIENCES, INC. via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Medicare reimbursement issues for medical device.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INARI MEDICAL via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Medicare coverage of transvenous (catheter) pulmonary embolectomy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth.; issues related to COVID-19 testing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE, White House Office
TRANSUNION via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Issues related to the Health IT Advisory Committee; H.R. 2503, Social Determinants Accelerator Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INARI MEDICAL via AKIN GUMP STRAUSS HAUER & FELD
2021 · second_quarter · Q2
Medicare coverage of transvenous (catheter) pulmonary embolectomy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2021 · second_quarter · Q2
COVID-19 pandemic response; Issues regarding telehealth
COVID-19 pandemic response; Issues regarding Medicare reimbursement for DMEPOS
Filing targets: HOUSE OF REPRESENTATIVES
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2021 · second_quarter · Q2
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TEXAS ASSOCIATION FOR HOME CARE & HOSPICE via AKIN GUMP STRAUSS HAUER & FELD
2021 · second_quarter · Q2
Issues related to home care and hospice, telehealth, Medicare reimbursement and state's health insurance program legislation.; Legislative and regulatory proposals affecting home care and hospice.; Home health rural add on payment adjustment.; Value based purchasing and bundling.; Hospice payment policy.; Home health non-physician certification authority.; Chronic care management proposals.; Medicare Advantage hospice proposals.; CMS Home Health Conditions of Participation.; Home Health Pre-Claim Review Demonstration program.; Disposal of controlled substances.; Review Choice Demonstration; Impact of COVID-19, including telehealth.; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response.
Issues related to home care and hospice, telehealth, Medicare reimbursement and state's health insurance program legislation.; Legislative and regulatory proposals affecting home care and hospice.; Home health rural add on payment adjustment.; Value based purchasing and bundling.; Hospice payment policy.; Home health non-physician certification authority.; Chronic care management proposals.; Medicare Advantage hospice proposals.; CMS Home Health Conditions of Participation.; Home Health Pre-Claim Review Demonstration program.; Disposal of controlled substances.; Review Choice Demonstration; Impact of COVID-19, including telehealth.; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response; Issues related to home care and hospice, telehealth, Medicare reimbursement.; Impact of COVID-19, including telehealth and the Provider Relief Fund.; COVID-19 relief funding within the American Rescue Plan Act (P.L. 117-2), HEAT Act (S. 4854/H.R.3371),; FY 2022 Appropriations, 1115 Waiver, and FMAP increase/HCBS.; HEAT Act (H.R. 3371).
TRANSUNION via AKIN GUMP STRAUSS HAUER & FELD
2021 · second_quarter · Q2
Social Determinants Accelerator Act of 2021 (H.R. 2503)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2021 · second_quarter · Q2
Air Ambulance and Patient Billing Advisory Committee, and implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); eliminating the Provider Relief Fund Tax Penalties Act of 2021 (H.R. 2079)
Advocacy regarding Medicare reimbursement for emergency air ambulance services.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INARI MEDICAL via AKIN GUMP STRAUSS HAUER & FELD
2021 · second_quarter · RR
Issues related to Medicare reimbursement.
Issues related to Medicare reimbursement.
TRANSUNION via AKIN GUMP STRAUSS HAUER & FELD
2021 · first_quarter · Q1
Issues related to Medicare reimbursement and state all-payer claims databases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2021 · first_quarter · Q1
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SENSEONICS INCORPORATED via AKIN GUMP STRAUSS HAUER & FELD
2021 · first_quarter · Q1
Issues relates to Medicare reimbursement for an implantable device.; Issues with Medicare reimbursement; Issues relating to Medicare Physician Fee Schedule (PFS)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2021 · first_quarter · Q1
COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2022 Appropriations; Telehealth.
COVID-19 pandemic response; Supply chain reform; American Rescue Plan Act (P.L. 117-2); FY 2022 Appropriations; Telehealth.
APPRISS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2021 · first_quarter · Q1
Legislative efforts related to prescription drug monitoring programs (PDMPs), including the implementation of PDMP provisions in the VA MISSION Act of 2018 (P.L. 115-182).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AKEBIA THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2021 · first_quarter · Q1
Issues with Medicare reimbursement; Issues relating to CY 21 End Stage Renal Disease (ESRD) Prospective Payment System; Medicare flexibility related to COVID-19 pandemic outbreak.
Issues with Medicare reimbursement; Issues relating to CY 21 End Stage Renal Disease (ESRD) Prospective Payment System; Medicare flexibility related to COVID-19 pandemic outbreak.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2020 · first_quarter · 1A
Telemonitoring; competitive bidding and ventilator coverage policy; Interim Final Rule on DMEPOS; Round 2021 of the Competitive Bidding Program; SMART Act (H.R. 4945); CARES Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2020 · first_quarter · 1A
Issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
SIGHT SCIENCES, INC. via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · Q4
Reimbursement issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · Q4
Implementation of and funding for SUPPORT Act legislation related to addressing the opioid crisis and additional addiction issues, including H.R. 2482/S. 2074, H.R. 3734/S. 1448, and S. 1012/H.R. 2062 education re Shatterproof's Addiction Treatment Locator, Analysis, and Standards (ATLAS) tool addiction prevention and assistance efforts in the workplace and advise client regarding federal legislative and regulatory response to the COVID-19 Cares Act and other federal initiatives as they relate to the quality of, and access to substance use disorder treatment. Implementation of and funding for SUPPORT for Patients and Communities Act (P.L. 115-271) legislation related to addressing the opioid crisis and additional addiction issues, including the Mainstreaming Addiction Treatment Act (H.R. 2482/S. 2074) Medication Access and Training Expansion Act (H.R. 2482); PDMPs Help Patients Act of 2019 (H.R. 3927); Consolidated Appropriations Act, 2021 (H.R. 133).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SENSEONICS INCORPORATED via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · Q4
Issues relates to Medicare reimbursement for an implantable device.; Issues with Medicare reimbursement; Issues relating to Medicare Physician Fee Schedule (PFS)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · Q4
H.R. 133, Consolidated Appropriations Act, 2021; issues regarding telehealth.
Delay of Round 2021 of the Competitive Bidding Program; coverage policies regarding noninvasive positive pressure ventilation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · Q4
Issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office
FMR LLC via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · Q4
Legislative efforts related to expansion and modernization of health savings accounts (HSA); implementation of international tax reform provisions; issues related to student loans. Issues related to Covid.
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, Treasury, Dept of
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · Q4
Medicare reimbursement for Part B drugs administered at home.
Drug pricing issues, including the IPI Drug Pricing Model; Prescription Drug Pricing Act (S. 2543); Lower Costs, More Cures Act (H.R. 19/S. 3129); Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Drug importation; Home health options for Medicare Part B drugs related to the CARES Act (H.R. 748); The Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074); Home infusion flexibilities during COVID-19 pandemic; DISARM legislation re antimicrobial resistance and other congressional proposals; Rare Pediatric Disease Priority Review Program
Filing targets: SENATE
APPRISS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · Q4
Legislative efforts related to prescription drug monitoring programs (PDMPs), including the PDMPs Help Patients Act (H.R. 3927); implementation of PDMP provisions of H.R. 6, the SUPPORT Act; education re developments in PDMP technology; education re developments in COVID-19 data reporting technology.
Filing targets: Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · Q4
Advocacy regarding solutions to address balance billing and preserve access to emergency air ambulance services, particularly in rural areas, including the Consolidated Appropriations Act, 2021 (H.R. 133), Lower Health Care Costs Act (S. 1895), No Surprises Act (H.R. 3630), Ban Surprise Billing Act (H.R. 5800), Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826), the Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074), and CARES Act (H.R. 748); Paycheck Protection Program and Health Care Enhancement Act (H.R. 266); support for air ambulance cost and claims data reporting program; support for emergency first responder COVID-19 relief.
Advocacy regarding Medicare reimbursement for emergency air ambulance services, the Air Ambulance and Patient Billing Advisory Committee, and COVID-19 reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE, White House Office
EMPRESAS FONALLEDAS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · 3A
Medicaid and Medicare recourses for Puerto Rico.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIGHT SCIENCES, INC. via AKIN GUMP STRAUSS HAUER & FELD
2020 · fourth_quarter · RR
Reimbursement issues for ophthalmology surgical services.
Reimbursement issues for ophthalmology surgical services.
SURGERY PARTNERS via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · Q3
Implementation of CARES Act (H.R. 748); Paycheck Protection Program and Health Care Enhancement Act (H.R. 266); relief for ASCs related to COVID-19 pandemic outbreak.
Implementation of CARES Act (H.R. 748); Paycheck Protection Program and Health Care Enhancement Act (H.R. 266); relief for ASCs related to COVID-19 pandemic outbreak.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · Q3
Implementation of and funding for SUPPORT Act; legislation related to addressing the opioid crisis and additional addiction issues, including H.R. 2482/S. 2074, H.R. 3734/S. 1448, and S. 1012/H.R. 2062; education re Shatterproofs Addiction Treatment Locator, Analysis, and Standards (ATLAS) tool; addiction prevention and assistance efforts in the workplace; and advise client regarding federal legislative and regulatory response to the COVID-19 Cares Act and other federal initiatives as they relate to the quality of, and access to substance use disorder treatment.; Implementation of and funding for SUPPORT for Patients and Communities Act (P.L. 115-271); legislation related to addressing the opioid crisis and additional addiction issues, including the Mainstreaming Addiction Treatment Act (H.R. 2482/S. 2074); Medication Access and Training Expansion Act (H.R. 2482); PDMPs Help Patients Act of 2019 (H.R. 3927).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · Q3
Delay of Round 2021 of the Competitive Bidding Program; SMART Act (H.R. 4945); Coverage policies regarding noninvasive positive pressure ventilation.
CARES Act (H.R. 748); Telehealth; Strategic National Stockpile; Paycheck Protection Program and Health Care Enhancement Act (H.R. 266)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · Q3
Advocacy regarding solutions to address balance billing and preserve access to emergency air ambulance services, particularly in rural areas, including the Lower Health Care Costs Act (S. 1895), No Surprises Act (H.R. 3630), Ban Surprise Billing Act (H.R. 5800), Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826), the Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074), and CARES Act (H.R. 748); implementation of Paycheck Protection Program and Health Care Enhancement Act (H.R. 266); support for air ambulance cost and claims data reporting program; support for emergency first responder COVID-19 relief.
Advocacy regarding Medicare reimbursement for emergency air ambulance services, the Air Ambulance and Patient Billing Advisory Committee, and CMS report on air ambulance costs (P.L. 116-93).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE, Transportation, Dept of (DOT), White House Office
MEMORIAL SLOAN-KETTERING CANCER CENTER via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · 3T
Issues related to radiation oncology alternative payment model.
Filing targets: Health & Human Services, Dept of (HHS)
FMR LLC via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · Q3
Legislative efforts related to expansion and modernization of health savings accounts (HSA); implementation of international tax reform provisions; issues related to student loans. Issues related to Covid.
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, Treasury, Dept of
EMPRESAS FONALLEDAS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · Q3
Medicaid and Medicare recourses for Puerto Rico.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · Q3
Drug pricing issues, including the IPI Drug Pricing Model; Prescription Drug Pricing Act (S. 2543); Lower Costs, More Cures Act (H.R. 19/S. 3129); Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Drug importation; Home health options for Medicare Part B drugs related to the CARES Act (H.R. 748); The Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074); Home infusion flexibilities during COVID-19 pandemic; DISARM legislation re antimicrobial resistance and other congressional proposals; Rare Pediatric Disease Priority Review Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APPRISS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · Q3
Legislative efforts related to prescription drug monitoring programs (PDMPs), including the PDMPs Help Patients Act (H.R. 3927); implementation of PDMP provisions of H.R. 6, the SUPPORT Act; education re developments in PDMP technology; education re developments in COVID-19 data reporting technology.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
AKEBIA THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2020 · third_quarter · Q3
Issues with Medicare reimbursement; Issues relating to CY 20 End Stage Renal Disease (ESRD) Prospective Payment System; Medicare flexibility related to COVID-19 pandemic outbreak.
Issues with Medicare reimbursement; Issues relating to CY 20 End Stage Renal Disease (ESRD) Prospective Payment System; Medicare flexibility related to COVID-19 pandemic outbreak.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
Advocacy regarding the Air Ambulance and Patient Billing Advisory Committee and ensuring access to emergency air ambulance services.
Advocacy regarding Medicare reimbursement for emergency air ambulance services, the Air Ambulance and Patient Billing Advisory Committee, and CMS report on air ambulance costs (P.L. 116-93).
Advocacy regarding solutions to address balance billing and preserve access to emergency air ambulance services, particularly in rural areas, including the Lower Health Care Costs Act (S. 1895), No Surprises Act (H.R. 3630), Ban Surprise Billing Act (H.R. 5800), Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826), the Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074), and CARES Act (H.R. 748); Paycheck Protection Program and Health Care Enhancement Act (H.R. 266); support for air ambulance cost and claims data reporting program; support for emergency first responder COVID-19 relief.
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
Telemonitoring; competitive bidding and ventilator coverage policy; Interim Final Rule on DMEPOS; Round 2021 of the Competitive Bidding Program; SMART Act (H.R. 4945); CARES Act; Telehealth; Strategic National Stockpile; Paycheck Protection Program and Health Care Enhancement Act (H.R. 266); issues regarding Coronavirus Commission for Safety and Quality in Nursing Homes
Delay of Round 2021 of the Competitive Bidding Program; SMART Act (H.R. 4945); coverage policies regarding noninvasive positive pressure ventilation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SENSEONICS INCORPORATED via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
Issues relates to Medicare reimbursement for an implantable device.
COVID-19 health care issues including relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (H.R. 748)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
Implementation of and funding for SUPPORT Act; legislation related to addressing the opioid crisis and additional addiction issues, including H.R. 2482/S. 2074, H.R. 3734/S. 1448, and S. 1012/H.R. 2062; education re Shatterproofs Addiction Treatment Locator, Analysis, and Standards (ATLAS) tool; addiction prevention and assistance efforts in the workplace; and advise client regarding federal legislative and regulatory response to the COVID-19 Cares Act and other federal initiatives as they relate to the quality of, and access to substance use disorder treatment.; Implementation of and funding for SUPPORT for Patients and Communities Act (P.L. 115-271); legislation related to addressing the opioid crisis and additional addiction issues, including the Mainstreaming Addiction Treatment Act (H.R. 2482/S. 2074); Medication Access and Training Expansion Act (H.R. 2482); PDMPs Help Patients Act of 2019 (H.R. 3927).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SURGERY PARTNERS via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
CARES Act (H.R. 748); Paycheck Protection Program and Health Care Enhancement Act (H.R. 266); Immediate Relief for Rural Facilities and Providers Act of 2020 (S. 3559/H.R. 6365); relief for ASCs related to COVID-19 pandemic outbreak.
CARES Act (H.R. 748); Paycheck Protection Program and Health Care Enhancement Act (H.R. 266); To amend title XVIII of the Social Security Act to provide for forgiveness of certain accelerated and advance payments under parts A and B of the Medicare program (H.R. 7292); relief for ASCs related to COVID-19 pandemic outbreak.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FMR LLC via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
Legislative efforts related to expansion and modernization of health savings accounts (HSA); implementation of international tax reform provisions; issues related to student loans. Issues related to Covid.
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, Treasury, Dept of
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
Drug pricing issues, including the IPI Drug Pricing Model; Prescription Drug Pricing Act (S. 2543); Lower Costs, More Cures Act (H.R. 19/S. 3129); Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); drug importation and other congressional proposals; home health options for Medicare Part B drugs related to the CARES Act (H.R. 748); the Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074); home infusion flexibilities during COVID-19 pandemic
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APPRISS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
Legislation related to prescription drug monitoring programs (PDMPs), including the PDMPs Help Patients Act (H.R. 3927); implementation of PDMP provisions of H.R. 6, the SUPPORT Act; education re developments in PDMP technology.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
XENEX DISINFECTION SERVICES, LLC via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
Seek utilization of full-germicidal spectrum UV technologies for the COVID-19 pandemic. Outreach regarding National Defense Authorization Act (S. 4049/HR 6395).
Filing targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of the Vice President of the United States, SENATE, Veterans Affairs, Dept of (VA)
AKEBIA THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2020 · second_quarter · Q2
Issues with Medicare reimbursement; Issues relating to CY 20 End Stage Renal Disease (ESRD) Prospective Payment System; Medicare flexibility related to COVID-19 pandemic outbreak.
Issues with Medicare reimbursement; Issues relating to CY 20 End Stage Renal Disease (ESRD) Prospective Payment System; Medicare flexibility related to COVID-19 pandemic outbreak.edicare reimbursement; Issues relating to CY 20 End Stage Renal Disease (ESRD) Prospective Payment System; Medicare flexibility related to COVID-19 pandemic outbreak.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Issues related to home care and hospice, telehealth, Medicare reimbursement and state's health insurance program legislation.; Legislative and regulatory proposals affecting home care and hospice.; Home health rural add on payment adjustment.; Value based purchasing and bundling.; Hospice payment policy.; Home health non-physician certification authority.; Chronic care management proposals.; Medicare Advantage hospice proposals.; CMS Home Health Conditions of Participation.; Home Health Pre-Claim Review Demonstration program.; Disposal of controlled substances.; Review Choice Demonstration; Impact of COVID-19, including telehealth.; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office